The financial effects of kidney stone prevention

Abstract

Prevention of nephrolithiasis (NL) is now medically feasible and widely recommended. However, diagnosis and treatment of remediable causes of stones requires testing and drugs that impose a cost; this cost is balanced by the presumed reductions in stone related events and medical encounters. In order to assess the balance between these, we have analyzed results from 1092 patients with NL unselected except for having clinical follow-up during treatment. From this population, we have derived the changes in rates of new stones, hospitalizations, cystoscopies, and surgical procedures. From these changes, and assignment of a range of possible dollar costs, we estimate that medical stone prevention will result in an average saving of $2,158 +/- $500 (SEM)/patient/year, which is the difference between an expenditure of $1,068/patient on yearly drugs and testing, and a reduction of $3,226 per patient in medical costs. Medical prevention of NL seems justified on a cost saving basis quite apart from its benefits to patients in terms of reduced morbidity and risk from procedures, obstruction, and infection.